CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	8.24M -79.8%
Revenue (ttm)	2.48M +280.8%
Net Income	-12.16M
EPS	-1.02
Shares Out	14.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,811
Open	0.5900
Previous Close	0.5900
Day's Range	0.5706 - 0.5900
52-Week Range	0.5500 - 4.9800
Beta	0.81
Analysts	Buy
Price Target	11.00 (+1,823.08%)
Earnings Date	Mar 25, 2026

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixF...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN
• Website: https://collplant.com

Financial Performance

In 2024, CollPlant Biotechnologies's revenue was $515,000, a decrease of -95.30% compared to the previous year's $10.96 million. Losses were -$16.61 million, 136.6% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CLGN stock is "Buy." The 12-month stock price target is $11.0, which is an increase of 1,823.08% from the latest price.

Price Target

$11.0

(1,823.08% upside)

Analyst Consensus: Buy